Literature DB >> 8256804

Evaluation of families wherein a single male manifests a phenotype of X-linked lymphoproliferative disease (XLP).

H L Grierson1, J Skare, J Church, T Silberman, J R Davis, N Kobrinsky, R McGregor, S Israels, J McCarty, L G Andrews.   

Abstract

The Epstein-Barr virus (EBV)-induced diseases of males with X-linked lymphoproliferative disease (XLP) include fatal infectious mononucleosis (IM), non-Hodgkin lymphoma (ML), agammaglobulinemia, and aplastic anemia. These phenotypes also occur as sporadic cases in families, and EBV seronegative males in these families must be considered at risk for XLP until they seroconvert normally to EBV. Given that 50% of males inheriting the defective XLP gene die following primary EBV infection, it is vital that they be identified pre-EBV infection. Here we report results using molecular genetic techniques to provide information as to the relative risks of EBV negative males and potential carrier females in ten families wherein a single male had died of IM.

Entities:  

Mesh:

Year:  1993        PMID: 8256804     DOI: 10.1002/ajmg.1320470404

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  3 in total

1.  X-linked lymphoproliferative disease: three atypical cases.

Authors:  K Nistala; K C Gilmour; T Cranston; E G Davies; D Goldblatt; H B Gaspar; A M Jones
Journal:  Clin Exp Immunol       Date:  2001-10       Impact factor: 4.330

2.  Identification of an SH2D1A mutation in a hypogammaglobulinemic male patient with a diagnosis of common variable immunodeficiency.

Authors:  Asghar Aghamohammadi; Hirokazu Kanegane; Mostafa Moein; Abolhasan Farhoudi; Zahra Pourpak; Masoud Movahedi; Mohammad Gharagozlou; Ali Akabar Amir Zargar; Toshio Miyawaki
Journal:  Int J Hematol       Date:  2003-07       Impact factor: 2.490

3.  X linked lymphoproliferative disease in a United Kingdom family.

Authors:  P D Arkwright; G Makin; A M Will; M Ayres; D A Gokhale; W D Fergusson; G M Taylor
Journal:  Arch Dis Child       Date:  1998-07       Impact factor: 3.791

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.